| 叶山东.胰高糖素样肽-1受体激动剂保护动脉粥样硬化性心血管疾病循证证据的研究进展[J].中国临床保健杂志,2025,28(5):623-627. |
| 胰高糖素样肽-1受体激动剂保护动脉粥样硬化性心血管疾病循证证据的研究进展 |
| Progress of GLP-1 receptor agonists in protecting atherosclerotic cardiovascular disease based on evidence-based evidence |
| 投稿时间：2025-03-10 |
| DOI：10.3969/J.issn.1672-6790.2025.05.007 |
| 中文关键词: 心血管疾病 动脉粥样硬化 糖尿病 受体,胰岛淀粉样多肽 循证医学 |
| 英文关键词: Cardiovascular diseases Atherosclerosis Diabetes mellitus Receptors,islet amyloid polypeptide Evidence-based medicine 〖FL |
| 基金项目: |
|
| 摘要点击次数: 42 |
| 全文下载次数: 19 |
| 中文摘要: |
| 糖尿病是动脉粥样硬化性心血管疾病(ASCVD)的重要危险因素。糖尿病患者ASCVD发生风险是普通人群的2~4倍。胰高糖素样肽受体激动剂(GLP-1RA)是一安全有效的抗糖尿病药物。近年来许多大样本循证研究证据,尤其来自心血管疾病结局试验(CVOT)的结果显示,GLP-1RA对ASCVD存在明确的保护作用,其机制尚不是十分清楚。本文重点整理分析了GLP-1RA对ASCVD影响的临床研究结果,并探讨其可能的机制。 |
| 英文摘要: |
| Diabetes mellitus is an important risk factor for atherosclerotic cardiovascular disease (ASCVD),the risk of ASCVD in diabetic patients is 2-4 times higher than that of general population.Glucagon peptide(GLP)-1 receptor agonist is a kind of safe and effective antidiabetic drug.In recent years,many evidence-based studies,especially from the Cardiovascular Disease Outcome Trial (CVOT),have shown that GLP-1 receptor agonists also have a clear protective effect on ASCVD,and the mechanism is not very clear.This paper focuses on sorting out and analyzing the results of clinical studies on the effects of GLP-1 receptor agonists on ASCVD and exploring the possible mechanisms. |
|
查看全文
|
| 关闭 |